Dennis Podlesak Sells 11,975 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXGet Rating) Director Dennis Podlesak sold 11,975 shares of Syndax Pharmaceuticals stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $23.43, for a total value of $280,574.25. Following the completion of the sale, the director now directly owns 75,763 shares in the company, valued at $1,775,127.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Syndax Pharmaceuticals Trading Down 5.8 %

Shares of NASDAQ SNDX opened at $23.14 on Friday. The business’s 50 day moving average is $22.52 and its two-hundred day moving average is $18.89. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.69 and a quick ratio of 12.69. Syndax Pharmaceuticals, Inc. has a 1-year low of $13.27 and a 1-year high of $25.71. The stock has a market capitalization of $1.31 billion, a P/E ratio of 144.63 and a beta of 1.24.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.03. Syndax Pharmaceuticals had a return on equity of 0.24% and a net margin of 17.84%. As a group, research analysts expect that Syndax Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. B. Riley reaffirmed a “buy” rating and issued a $31.00 target price on shares of Syndax Pharmaceuticals in a report on Thursday, July 28th. The Goldman Sachs Group reduced their price objective on Syndax Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 9th. Finally, Robert W. Baird boosted their price objective on Syndax Pharmaceuticals to $32.00 in a research note on Monday, August 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SNDX. Bank of America Corp DE boosted its position in shares of Syndax Pharmaceuticals by 109.5% during the fourth quarter. Bank of America Corp DE now owns 188,937 shares of the company’s stock valued at $4,135,000 after buying an additional 98,760 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Syndax Pharmaceuticals by 22.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 793,700 shares of the company’s stock valued at $17,374,000 after buying an additional 145,674 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of Syndax Pharmaceuticals by 544.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 68,399 shares of the company’s stock valued at $1,497,000 after buying an additional 57,779 shares during the period. Citigroup Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 140.6% in the fourth quarter. Citigroup Inc. now owns 130,087 shares of the company’s stock valued at $2,848,000 after purchasing an additional 76,023 shares during the period. Finally, Allianz Asset Management GmbH purchased a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at approximately $1,624,000. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Syndax Pharmaceuticals Company Profile

(Get Rating)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).

Featured Articles

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.